Protagonist Therapeutics, Inc. (PTGX) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Protagonist Therapeutics, Inc. (PTGX) Healthcare & Pipeline Overview

Protagonist Therapeutics, Inc. specializes in peptide-based therapeutics aimed at treating hematology and inflammatory diseases, leveraging a robust clinical pipeline and strategic collaborations to address significant unmet medical needs.

What Is the Investment Thesis for PTGX?

The company's lead candidate, rusfertide, targets significant market opportunities in hematology, with potential to capture a share of the estimated $5 billion market for treatments of polycythemia vera and hereditary hemochromatosis. Additionally, the ongoing development of PN-943 and PN-235 in the IBD market, which is projected to reach $20 billion by 2028, positions Protagonist favorably within a growing therapeutic landscape. The collaboration with Janssen Biotech enhances Protagonist's market reach and R&D capabilities, potentially accelerating the commercialization of its products. However, the company faces risks related to clinical trial outcomes and regulatory approvals, which could impact its growth trajectory and market valuation.

Based on FMP financials and quantitative analysis

PTGX Key Highlights

Market capitalization of $9.37B, reflecting strong investor interest and confidence in the company's pipeline.

• Gross margin of 99.5%, indicating high potential profitability upon successful commercialization of products.
• Beta of 2.11, suggesting higher volatility compared to the broader market, which may appeal to certain risk-tolerant investors.
• Currently no dividend yield, consistent with many biotechnology firms focused on reinvestment for growth.
• Profit margin of -154.9%, typical for early-stage biotech firms investing heavily in R&D.

Who Are PTGX's Competitors?

PTGX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are PTGX's Key Strengths?

Strong clinical pipeline with multiple candidates in advanced stages of development.

• High gross margins indicative of potential profitability upon commercialization.
• Strategic collaborations enhancing research capabilities and market access.

What Are PTGX's Weaknesses?

Negative profit margins typical of early-stage biotechnology firms.

• Dependence on successful clinical trial outcomes for future growth.
• Limited revenue streams until product commercialization.

What Could Drive PTGX Stock Higher?

PTGX catalyst: Results from Phase II clinical trials for rusfertide (PTG-300) expected in the next 12 months.

• Collaboration with Janssen Biotech continues to enhance development and commercialization efforts.
• Initiation of additional clinical trials for PN-943 and PN-235 as data from current trials is analyzed.

What Are the Key Risks for PTGX?

Rich valuation — a P/E of 119.17 runs well above the Healthcare sector’s ~21.50x, leaving little room for a miss.

• Insider selling — insiders were net sellers of roughly $43.6M recently.
• Clinical trial outcomes may not meet expectations, impacting product viability.
• Dependence on external partnerships for development and commercialization success.
• Regulatory challenges could delay or prevent product approvals.

What Are the Growth Opportunities for PTGX?

• Growth opportunity 1: The ongoing clinical trials for rusfertide (PTG-300) are a significant growth driver, targeting a market estimated at $5 billion for polycythemia vera and hereditary hemochromatosis. As the drug progresses through Phase II trials, successful outcomes could lead to accelerated approval pathways, potentially bringing the product to market within the next 2-3 years.
• Growth opportunity 2: Protagonist's development of PN-943 for inflammatory bowel disease (IBD) taps into a rapidly expanding market projected to reach $20 billion by 2028. With increasing prevalence rates of IBD and a growing demand for effective treatments, successful clinical results could position PN-943 as a leading therapy in this lucrative space.
• Growth opportunity 3: The collaboration with Janssen Biotech enhances Protagonist's development capabilities and market access, providing additional resources for advancing its clinical pipeline. This partnership could lead to co-development opportunities and shared commercialization efforts, significantly accelerating the time to market for key products.
• Growth opportunity 4: The potential for expanding the indications of PN-235 beyond IBD to other autoimmune disorders presents a strategic avenue for growth. As the understanding of interleukin-23's role in various diseases evolves, Protagonist could capitalize on additional therapeutic markets, further diversifying its revenue streams.
• Growth opportunity 5: Continued investment in R&D and the exploration of new peptide-based therapies could lead to additional product candidates entering the pipeline. By leveraging its expertise in peptide therapeutics, Protagonist can innovate and address unmet medical needs across various therapeutic areas, enhancing its long-term growth prospects.

What Threats Does PTGX Face?

• Intense competition from established and emerging biotechnology firms.
• Regulatory hurdles that may delay product approvals.
• Market volatility affecting funding and investment in biotechnology.

What Are PTGX's Competitive Advantages?

• Strong intellectual property portfolio protecting proprietary peptide technologies.
• Established collaborations with major pharmaceutical companies like Janssen Biotech, enhancing credibility and market access.
• Focused expertise in peptide therapeutics, providing a competitive edge in drug development.

What Does PTGX Do?

Founded in 2006 and headquartered in Newark, California, Protagonist Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and developing peptide-based therapeutic drugs. The company primarily focuses on addressing hematology and blood disorders, as well as inflammatory and immunomodulatory diseases. Protagonist's lead product candidate, rusfertide (PTG-300), is an injectable hepcidin mimetic currently in Phase II clinical trials for the treatment of polycythemia vera and hereditary hemochromatosis, along with other blood disorders. Additionally, the company is advancing PN-943, an oral, alpha-4-beta-7 integrin-specific antagonist peptide, which is also in Phase II trials aimed at treating inflammatory bowel disease (IBD). Another promising candidate, PN-235, is an orally delivered interleukin-23 receptor-specific antagonist intended for IBD and non-IBD indications. Protagonist has established a license and collaboration agreement with Janssen Biotech, Inc., enhancing its capabilities in drug development and commercialization. With a dedicated workforce of 124 employees, Protagonist Therapeutics has positioned itself as a key player in the biotechnology sector, focusing on innovative solutions for complex medical challenges.

What Products and Services Does PTGX Offer?

• Develops peptide-based therapeutic drugs targeting hematology and blood disorders.
• Conducts clinical trials for innovative treatments addressing inflammatory and immunomodulatory diseases.
• Focuses on injectable and oral drug formulations for improved patient compliance.
• Collaborates with established biopharmaceutical companies to enhance development capabilities.
• Targets significant unmet medical needs in complex disease areas.

How Does PTGX Make Money?

• Generates revenue through partnerships and collaborations with larger pharmaceutical companies.
• Plans to monetize its drug candidates upon successful clinical trials and regulatory approvals.
• Focuses on R&D investments to develop innovative therapies that address critical health issues.

What Industry Does PTGX Operate In?

The biotechnology industry is experiencing robust growth, driven by advancements in drug development technologies and increasing demand for innovative therapies. The global biotechnology market is projected to reach approximately $2.4 trillion by 2028, with significant contributions from hematology and inflammatory disease sectors. Protagonist Therapeutics operates within this dynamic landscape, competing with companies such as Arcellx, Inc. (ACLX), Alkermes plc (ALKS), TG Therapeutics, Inc. (TGTX), PTC Therapeutics, Inc. (PTCT), and Immunovant, Inc. (IMVT). These competitors are also developing novel therapies, intensifying the competition for market share in targeted therapeutic areas.

Who Are PTGX's Key Customers?

• Healthcare providers seeking innovative treatment options for patients with blood disorders.
• Pharmaceutical companies interested in collaboration and licensing agreements.
• Patients suffering from hematology and inflammatory diseases requiring effective therapies.

Over the past six months, Protagonist Therapeutics, Inc. insiders filed 48 SEC Form 4 transactions — 33 sales and 15 purchases. On net that is roughly 433K shares disposed (about $43.6M), a signal worth weighing alongside the fundamentals.

Quarterly Financial Performance: Protagonist Therapeutics, Inc.

Revenue for Protagonist Therapeutics, Inc. came in at $213.5M during Q2 FY2026, a 278.7% improvement versus the preceding quarter. The company recorded net income of $162.8M, with diluted EPS of $2.29. Revenue has increased across the last three reported quarters, suggesting sustained momentum for this mid-cap Healthcare company. Across the four most recent quarters, PTGX averaged $0.26 in diluted EPS.

PTGX Valuation & Market Position

With a $9.37B market cap, Protagonist Therapeutics, Inc. sits in the mid-cap segment of the market. Analyst price targets span from $121.00 to $190.00, with a consensus of $169.38. At the current price of $145.64, that implies approximately 16% upside potential. Relative to its peer group, PTGX's quantitative score of 77/100 is roughly in line with the peer average of 72/100.

Return on equity for Protagonist Therapeutics, Inc. stands at 12.0%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 9.4%, showing how much profit it generates from its asset base. PTGX trades at a trailing price-to-earnings ratio of 119.17, above the Healthcare sector average of ~21.50x. Its free cash flow yield is 1.4%, a gauge of the cash the business throws off relative to its market value. A current ratio of 21.71 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 0.9%, the inverse of the P/E and a quick read on earnings relative to price.

Protagonist Therapeutics, Inc.'s Piotroski F-Score is 6/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile.

Protagonist Therapeutics, Inc. has beaten Wall Street's EPS estimate in 5 of its last 8 reported quarters — more hits than misses. Reported results have landed about 417.7% above estimates on average.

Company Profile

Protagonist Therapeutics, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Newark, US. The company is led by CEO Dinesh V. Patel. PTGX has traded publicly since 2016.

PTGX Financials

PTGX Latest News

PTGX Analyst Consensus

PTGX MoonshotScore

What Investors Ask About Protagonist Therapeutics, Inc. (PTGX) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources